Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04248855 · ClinicalTrials.gov registry record · Phase 1
Assessment of KAN-101 in Celiac Disease (ACeD)
A Phase 1 study, sponsored by Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
NCT04248855: Completed Phase 1 study, sponsored by Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion.
NCT04248855 is a Phase 1 study that has completed, run by Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion. The registered enrollment target is 41 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (32% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04248855, a Phase 1 study, has completed, sponsored by Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
Study Summary
A safety study of KAN-101 in patients with celiac disease. The study has two parts: 1. Part A - first in human study in which patients receive a single dose of KAN-101 2. Part B - patients will receive three doses of either KAN-101 or placebo
Primary Outcome
Incidence and severity of treatment-emergent adverse events (TEAEs) as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 or higher
Interventions
- DRUG Placebo
- DRUG KAN-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2020-01-21 |
| Est. Completion | 2021-10-08 |
| Phase | Phase 1 |
What the finished NCT04248855 record still lists
NCT04248855 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (32% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04248855 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04248855 about?
NCT04248855 is a clinical study titled "Assessment of KAN-101 in Celiac Disease (ACeD)". A safety study of KAN-101 in patients with celiac disease. The study has two parts: 1. Part A - first in human study in which patients receive a single dose of KAN-101 2. Part B - patients will receive three doses of either KAN-101 or placebo
What is the current status of trial NCT04248855?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2020-01-21. Estimated completion is 2021-10-08.
What interventions are being tested in trial NCT04248855?
The interventions under investigation include: Placebo (DRUG), KAN-101 (DRUG).
Who is sponsoring clinical trial NCT04248855?
This trial is sponsored by Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04248855's enrollment target sits among peer trials
41 1125th of 2000 higher than 871 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI